MAYO CLINIC

SimX secures $1.25M AFWERX Phase II STTR grant to adapt its VR Medical Simulation System for perioperative expeditionary medical support training, collaborating with USF Health CAMLS to enhance healthcare training accessibility and effectiveness.

PDS Biotechnology announces a Key Opinion Leader event on Dec 17, 2024, to discuss HPV16-positive HNSCC and the VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab. Panelists include Dr. Francis Worden and Dr. Kevin Harrington, moderated by Dr. Kirk Shepard.

Caris Life Sciences and collaborators present seven studies on various breast cancer types, including male breast cancer, at the San Antonio Breast Cancer Symposium, highlighting the impact of Caris’ multimodal database on precision medicine.

FDA approves MENTOR™ MemoryGel™ Enhance Breast Implants for primary and revision reconstruction in post-mastectomy women, featuring sizes from 930 cc to 1445 cc, addressing the need for larger implants in women with larger breast cup sizes.

CG Oncology to host a conference call on Dec. 5 to discuss Phase 3 BOND-003 trial results of cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC, featuring Dr. Mark Tyson. Cretostimogene is an investigational oncolytic immunotherapy for NMIBC, with trials including BOND-003 and PIVOT-006. CG Oncology aims to develop bladder-sparing therapies for bladder cancer patients.

CG Oncology to host conference call and webcast on December 5, 2024, at 7 am CST to discuss Phase 3 BOND-003 trial results of cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC. Dr. Mark Tyson, II will present the results at the SUO 25th Annual Meeting in Dallas at 11:45 am CST. The webcast will be accessible via the company's Investor Relations website.

A new tool resembling a wiry flower at the end of a long tube is at the center of a multibillion-dollar race among Medtronic, Boston Scientific, and Johnson & Johnson MedTech to dominate the market for minimally invasive devices treating atrial fibrillation using pulsed field ablation (PFA). PFA, which uses electric pulses instead of heat or cooling, is expected to significantly reduce patient time in the cath lab and lower complication risks. Medtech executives view PFA as a transformative technology driving future growth, with Clarivate projecting PFA devices to exceed $1.3 billion in global sales this year.

Ascentage Pharma's olverembatinib, a third-generation BCR-ABL inhibitor, has its new indication for adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs) included in the China 2024 National Reimbursement Drug List (NRDL), effective January 1, 2025.

Shaji Kumar discusses 2024-2025 NCCN updates for multiple myeloma, highlighting quadruplet regimens as new standard care, tailored maintenance therapy, and major revisions for relapsed/refractory disease with immunotherapy integration, including CAR T-cell therapies and bispecific antibodies. Diagnostic approaches for smoldering myeloma were also updated.